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Orphan Drugs, only the Eculizumabe for the treatment of PNH has no approved 
registration by the National Health Surveillance Agency (ANVISA). ConClusions: 
Considering its high cost, high judicial demand and limited availability of scientific 
evidence, orphan drugs represent a challenge for researchers and decision makers. 
Clinical benefit, disease severity, availability of therapeutic alternatives, ethical, 
political and social aspects should be considered. It is necessary to start a multi-
disciplinary reflection on the development of HTA models and policies regarding 
rare diseases and innovative treatments in the SUS, as well as fostering the primary 
researches in this field.
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To WhaT ExTEnT Do DiSEaSE anD TrEaTmEnT CharaCTEriSTiCS 
influEnCE hTa-BaSED rECommEnDaTionS for a SamPlE of orPhan 
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DrugS havE a “SPECial STaTuS”?
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Routine HTA methods may not adequately capture all the important considerations 
of a treatment’s value and the impact of the condition on the patient given that 
evidence is often incomplete. This study aims to explore the influence of broader con-
siderations of scientific and social value judgments on reimbursement decisions for 
a sample of orphan drugs.objeCtives: To identify and compare the extent to which 
these broader considerations not captured by the incremental cost-effectiveness ratio 
(ICER) influenced HTA decision-making process in three countries; and, on this basis, 
explore whether orphan drugs have a “special status”. Methods: Countries included 
were England, Scotland and Sweden. Ten drug-indication pairs with EMA orphan des-
ignation and all appraised by NICE were selected. Publicly available HTA reports were 
coded using thematic analysis to systematically identify and compare these broader 
considerations across countries using an existing analytical framework. Results: 
108 different other considerations were identified and grouped into 15 clusters based 
on the information provided. The most common related to the nature of the disease, 
and considerations based on rarity or unmet need. 52% were one of the main reasons 
for the decision, and in some cases, were also a pivotal factor in accepting high and 
uncertain ICERs. Categorising these as social or scientific value judgments was done 
to identify areas where further elicitation of societal preferences, and where more 
consistency and transparency in their use are needed, respectively. Each of these was 
then compared to determine whether they pertained specifically to orphan drug or 
rare disease characteristics. ConClusions: Considerable variation was seen in the 
application of these broader considerations. Identifying these is a way forward to 
highlight areas where more research, or consistency and transparency are needed. 
Some of these other considerations may also favour orphan drugs, furthering the 
debate around whether orphan drugs deserve special status.
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WhY arE ThErE DiffErEnCES in hTa rECommEnDaTionS aCroSS 
CounTriES? a SYSTEmaTiC ComPariSon of hTa DECiSion ProCESSES for a 
SamPlE of orPhan DrugS in four CounTriES
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HTA reimbursement recommendations often result in different outcomes across 
countries despite the same evidence being appraised for a same technology. There 
is a need to understand the reasons for these differences. objeCtives: To system-
atically compare HTA processes for a sample of orphan drugs across four countries 
(England, Scotland, Sweden, France): to identify the use and interpretation of the evi-
dence appraised, and highlight differences across countries. Methods: Ten orphan 
drug-indication pairs were selected and systematically compared using a previously 
validated framework. An exploratory sequential mixed methods design divided the 
research into two stages: (1) qualitative in-depth analysis of the decision-making 
processes; and (2) quantitative identification of agency-specific risk preferences 
and agreement levels across countries. Results: Differences at each step of the 
decision-making process were identified. The same pivotal trials were appraised 
but with varying levels of detail in reporting the clinical outcomes, explaining some 
of the reasons for differing HTA recommendations. Agency-specific risk prefer-
ences were identified through correspondence analysis as drivers of these deci-
sions, further explaining some of these differences. Poor to moderate agreement in 
the interpretation of the evidence was measured using Cohen’s kappa scores. This 
reflected situations where the countries interpreted the same evidence differently 
and situations where differences in the handling of the same uncertainties were 
seen, including differences in the extent to which stakeholder input influenced a 
decision. ConClusions: This research systematically compared HTA processes 
in different countries, facilitating the understanding of these complex processes 
including how different HTA bodies conduct value assessments. It enabled to raise 
awareness around the reasons for differences across countries, and highlight 
areas for potential methodological improvements in HTA. Further application of 
this framework to other disease areas and countries is a way forward to improv-
ing the drivers of coverage decisions while better understanding the settings and 
limitations of HTA.
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objeCtives: Orphan drugs are highly priced and top 20 orphan drugs create almost 
2,5% of total drug expenditure in Slovakia. We conducted 8 years review of govern-
ment and literature sources to provide insight into pricing, reimbursement and 
availability situation surrounding top 20 orphan drugs in Slovakia from the health 
care payer perspective. Methods: We provide analysis of official prices, reim-
15% to 100%. In Italy only 9 molecules are reimbursed in retail pharmacy and other 
10 are not reimbursed at all. In 63% cases ex-factory prices in Italy are higher than 
in France. The average price difference in price is 12 % with 50% of products sharing 
almost same price (less than 5% difference). No information is available in France on 
managed entry agreement, while it is publicly available in Italy. This prevents fair 
price comparison. ConClusions: OD are more available in Italy, but reimburse-
ment is poorer than in France. Prices are slightly higher in Italy but France displays 
multiple confidential rebates making it impossible to compare net prices. In Italy 
the actual accessibility depends a lot on regional level unlike France.
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objeCtives: In Italy drug Health Technology Assessment (HTA) is conducted by the 
Scientific Technical Commission of Italian Medicines Agency (AIFA) with further 
negotiation between the manufacturers and the AIFA’s Pricing & Reimbursement 
Committee on price and reimbursement. After the decision is taken it is published 
in the official journal (Gazetta officale), the assessed drug is formally available 
for Italian patients next day. There does not exist a specific procedure for orphan 
drugs (OD), they are evaluated under the same conditions as drugs for common 
diseases. Pharmaco-economic studies are recommended for innovative drugs. The 
objective of the study is to review HTA decisions, prices and reimbursement of OD 
in Italy. Methods: All OD assessed in Italy since 2000 were identified. Prices, reim-
bursement rates and decision details were extracted for each drug using Farmadati 
Italia database. Results: Among 74 OD approved in Europe 66 molecules are offi-
cially available in Italy. It took 5-10 months from granting market authorization to 
final decision on pricing and reimbursement and publication in ‘Gazetta officale’. 
The mean time was about 17 months shorter than for common drugs. Only 9 of 
available molecules are fully reimbursed in Italy, reimbursement of 30 drugs is 
restricted to hospital use, 10 are not reimbursed and 5 are in a special class waiting 
a decision on reimbursement rate. For other drugs information is not available. Post-
marketing surveillance studies were requested for a half of indications, AIFA regis-
tries were reported in 25% of cases. Annual treatment ex-factory price of OD varies 
from € 2 500 to almost € 1 000 000. ConClusions: Almost 90% of approved OD are 
available in Italy. However, the actual situation often differs a lot from the official 
data as some drugs are unavailable from retail or hospital pharmacies. In addition, 
regional authorities contribute to inequity in access especially for “expensive drugs”.
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objeCtives: In France Orphan Drugs (OD) undergo the same Health Technology 
Assessment (HTA) procedure as other drugs. The evaluation is performed by the 
Transparency Committee (TC). Two scores are assigned and further used for pric-
ing & reimbursement decision: drug’s medical benefit (SMR) and improvement in 
medical benefit (ASMR). OD can be eligible to an accelerated procedure established 
for innovative products. The study aim is to analyse HTA decisions, prices and reim-
bursement of OD in France. Methods: Exhaustive prices, reimbursement and HTA 
opinions were extracted using Transparency Committee Website, AMELI’s national 
health insurance and Thériaque databases. Results: Among 74 OD approved 
in Europe, 21 drugs are not available in France. 6 were recently assessed by TC 
but are not yet reimbursed, 14 were not assessed and one got a negative opinion. 
Reimbursement process took between 2 and 5 months after TC opinion. 88% of 
drugs were considered as bringing a substantial medical benefit. At the same time, 
more than a half of medicines were graded as providing a major (9%), significant 
(27%) or moderate (20%) improvement in actual benefit leading to opportunity for 
premium prices, 30% were rated minor improvement, and about 14% no improve-
ment according to TC opinion. Annual treatment prices of OD varie from € 1,500 to 
almost € 1,000,000. ConClusions: About a third of approved ODs are not available 
in France. Most of them were authorized recently and are might become available 
after the HTA and pricing process. In comparison to non OD, the ASMR scoring is 
outstanding. Lack of alternative treatment and severity of the condition appear to 
be the drivers of high SMR-ASMR score.
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objeCtives: In Brazil, the studies produced by members of the Brazilian Network 
for Health Technology Assessment (REBRATS) have contributed in a significant way 
in the process of management and incorporation of technologies in the Brazilian 
Public Health system (SUS). However, there is still a lack of a Pharmaceutical 
Assistance and HTA Policy for rare diseases and the evidence for orphan drugs are 
limited and lower. The coverage for these drugs, is frequently done through judicial 
orders, political and social pressure, with no support of evidence-based medicine. 
The objectives is to evaluate the production of HTA studies for orphan drugs made 
by REBRATS members. Methods: Query to the REBRATS database and the internal 
production of the HTA coordination, prioritizing 6 major diseases: Gaucher dis-
ease, Fabry disease, Mucopolysaccharidosis Type I (MPS I); Mucopolysaccharidosis 
Type II (MPS II); Mucopolysaccharidosis Type VI (MPS VI); Paroxysmal Nocturnal 
Haemoglobinuria (PNH). Results: Five HTA studies were found, which are: a 
Rapid Response for Gaucher disease; a study on Health Technology Management 
for Fabry disease; an Economic Evaluation for MPS I, II and VI; a Systematic Review 
for Mucopolysaccharidosis Type II; and one Rapid Review for PNH. For the evaluated 
